Home » Posts tagged 'CSL Behring LLC'
Tag Archives: CSL Behring LLC
SEARCH THIS BLOG

Blog Stats
- 3,949,174 hits
Pages
- About me
- All about drugs
- Bioavailability
- CLINICAL TRIALS
- Combinatorial Chemistry in Drug Design
- DISCLAIMER
- Drug Basics
- DRUG COMPANIES
- DRUG DESIGN
- DRUG DISCOVERY
- Drug Information
- DRUG NEWS
- DRUG PORTALS
- Drug resistance
- DRUG SITES
- DRUG SYNTHESIS
- DRUGS NDA
- DRUGS, FDA2012
- FDA -US
- GMP
- HEALTH CANADA
- HELP ME/ ACCOLADES
- HSA SINGAPORE
- INDA
- KOREA DRUG APPROVAL PROCESS
- MHLW JAPAN, 厚生労働省
- NMPA CHINA
- PATENT EXPIRY DATES 1/3
- PATENT EXPIRY DATES 2/3
- PATENT EXPIRY DATES 3/3
- Patent portals
- Polymorphism
- Regulations and Guidance
- Scientificupdate (UK) on a roll
- sFDA CHINA
- SOUTH AFRICA, MCC
- SPECIAL DRUGS
- Traditional Medicine
- WHAT IS A DRUG
- World drug tracker
Archives
- June 2022 (7)
- May 2022 (5)
- April 2022 (7)
- March 2022 (7)
- February 2022 (12)
- January 2022 (15)
- December 2021 (26)
- November 2021 (17)
- October 2021 (21)
- September 2021 (21)
- August 2021 (19)
- July 2021 (13)
- June 2021 (30)
- May 2021 (7)
- April 2021 (9)
- March 2021 (25)
- February 2021 (10)
- January 2021 (17)
- December 2020 (21)
- November 2020 (5)
- October 2020 (5)
- September 2020 (12)
- August 2020 (3)
- July 2020 (5)
- June 2020 (1)
- May 2020 (1)
- April 2020 (1)
- March 2020 (19)
- February 2020 (9)
- January 2020 (12)
- December 2019 (4)
- November 2019 (4)
- October 2019 (11)
- September 2019 (8)
- August 2019 (14)
- July 2019 (23)
- June 2019 (15)
- May 2019 (16)
- April 2019 (21)
- March 2019 (14)
- February 2019 (7)
- January 2019 (17)
- December 2018 (7)
- November 2018 (14)
- October 2018 (12)
- September 2018 (18)
- August 2018 (22)
- July 2018 (15)
- June 2018 (38)
- May 2018 (14)
- April 2018 (19)
- March 2018 (25)
- February 2018 (15)
- January 2018 (17)
- December 2017 (20)
- November 2017 (15)
- October 2017 (19)
- September 2017 (8)
- August 2017 (13)
- July 2017 (11)
- June 2017 (6)
- May 2017 (10)
- April 2017 (23)
- March 2017 (18)
- February 2017 (17)
- January 2017 (15)
- December 2016 (19)
- November 2016 (31)
- October 2016 (38)
- September 2016 (33)
- August 2016 (40)
- July 2016 (53)
- June 2016 (50)
- May 2016 (50)
- April 2016 (70)
- March 2016 (45)
- February 2016 (49)
- January 2016 (42)
- December 2015 (37)
- November 2015 (37)
- October 2015 (49)
- September 2015 (35)
- August 2015 (29)
- July 2015 (25)
- June 2015 (28)
- May 2015 (21)
- April 2015 (41)
- March 2015 (51)
- February 2015 (23)
- January 2015 (33)
- December 2014 (46)
- November 2014 (31)
- October 2014 (38)
- September 2014 (74)
- August 2014 (86)
- July 2014 (101)
- June 2014 (170)
- May 2014 (98)
- April 2014 (113)
- March 2014 (80)
- February 2014 (63)
- January 2014 (70)
- December 2013 (100)
- November 2013 (91)
- October 2013 (102)
- September 2013 (104)
- August 2013 (114)
- July 2013 (129)
- June 2013 (131)
- May 2013 (155)
- April 2013 (109)
- March 2013 (105)
- February 2013 (81)
Categories
- 0rphan drug status (207)
- 2020 APPROVALS (48)
- accelerated approval (1)
- Acute Hepatic Porphyria (1)
- Acute myeloid leukaemia (1)
- African medicine (6)
- AIDS (7)
- Alzheimer's (3)
- ANAESTHETIC (1)
- anaesthetics (4)
- analgesic (2)
- ANALYTICAL (1)
- ANDA (5)
- Anthony crasto (38)
- ANTI ACNE (2)
- ANTI DIABETES (1)
- ANTI FUNGAL (6)
- ANTI INFLAMATORY (2)
- anti tubeculosis (1)
- antibacterial (9)
- Antibiotics (5)
- ANTIBODIES (54)
- ANTICONVULSANT (1)
- Antiemetic (2)
- antiglaucoma (1)
- Antihypertensives (2)
- antiinfluenza (2)
- antimalarials (12)
- Antineoplastic (6)
- antiobesity (1)
- Antispasmodic (1)
- ANTITUSSIVE (1)
- Antiulcerative (1)
- Antivirals (5)
- APPROVALS 2021 (82)
- APPROVALS 2022 (26)
- ARAB MEDICINE (5)
- Atopic dermatitis (1)
- Australia (1)
- AUSTRALIA 2021 (1)
- AWARD (11)
- AYURVEDA (78)
- Biosimilar drugs (39)
- BLA (4)
- BLOGS (26)
- Breakthrough Therapy Designation (67)
- canada (4)
- CANADA 2021 (1)
- cancer (154)
- cfda (6)
- CHINA 2011 (1)
- CHINA 2012 (1)
- CHINA 2018 (1)
- china 2019 (1)
- china pipeline (36)
- CHINESE HERBS (24)
- chronic kidney disease (1)
- CLINICAL TRIALS (10)
- COMPANIES (81)
- conference (5)
- Contrast agent (7)
- CORONAVIRUS (47)
- COVID-19 (45)
- CRL (1)
- CYSTIC FIBRIOSIS (1)
- Dengue (2)
- DIABETES (50)
- DNDi (1)
- Drug discovery (22)
- DRUG MARKETING (5)
- DRUG REVIEW (8)
- Duchenne muscular dystrophy (1)
- EMA (4)
- EU 2003 (1)
- EU 2005 (1)
- EU 2014 (5)
- EU 2015 (6)
- EU 2016 (4)
- EU 2017 (8)
- EU 2018 (5)
- EU 2020 (5)
- EU 2021 (11)
- EU 2022 (1)
- EU PIPELINE (61)
- EU SUBMISSION (32)
- EXTENDED USE (1)
- FAST TRACK FDA (74)
- FDA 15 (4)
- FDA 2010 (2)
- FDA 2011 (1)
- FDA 2012 (7)
- FDA 2013 (6)
- FDA 2014 (53)
- FDA 2015 (39)
- FDA 2016 (23)
- FDA 2017 (58)
- FDA 2018 (53)
- FDA 2019 (44)
- FDA 2020 (34)
- fda 2021 (45)
- FDA 2022 (13)
- Featured product (1)
- female sexual dysfunction (1)
- FIBROMYGALIA (1)
- flow synthesis (14)
- FORMULATION (14)
- GAIN (1)
- Gastric Proton Pump Inhibitor (1)
- Generating Antibiotic Incentives Now (1)
- GENERIC DRUG (106)
- GENERICS (22)
- glenmark (18)
- GLENMARK (16)
- GLIPTIN (1)
- GMP (10)
- gout (1)
- Greek medicine (3)
- hepatitis C viral infections (1)
- Herbals (8)
- HOMEOPATHY (3)
- HORMONE (1)
- Human medicines European Public Assessment Report EPAR (2)
- Hypertension (1)
- hypnotic (1)
- idiopathic pulmonary fibrosis (3)
- IMPLANTS (2)
- IND (1)
- IND 2017 (2)
- IND 2018 (3)
- IND 2021 (8)
- IND Filed (2)
- INDIA 2020 (5)
- INDIA 2022 (1)
- Insomnia (1)
- Investigational device exemption (IDE) approval (2)
- JAPAN 2009 (1)
- JAPAN 2013 (1)
- JAPAN 2014 (1)
- JAPAN 2015 (2)
- JAPAN 2016 (1)
- japan 2017 (6)
- JAPAN 2018 (10)
- japan 2019 (8)
- japan 2020 (10)
- JAPAN 2021 (11)
- JAPAN 2022 (10)
- Japan marketing (34)
- Japan pipeline (38)
- Korea (3)
- korea 2012 (2)
- korea 2016 (1)
- korea 2019 (1)
- Lactams (1)
- MAA (3)
- Macrolides (2)
- Malaria (17)
- MANUFACTURING (8)
- Market info (3)
- Marketing authorisation application EU (4)
- MEDICAL DEVICE (9)
- MIGRAINE (1)
- molybdenum cofactor deficiency (1)
- Monoclonal antibody (88)
- Nanotechnology (5)
- NCE (2)
- NDA (52)
- NDA JAPAN (3)
- neuropathic pain (1)
- Neutraceuticals (1)
- New Drug Application Resubmission FDA (5)
- NEW DRUGS (76)
- New drugs canada (5)
- New drugs china (6)
- New drugs EU (10)
- New drugs Japan (2)
- NEW USE DRUGS (1)
- Newzealand (2)
- NICE (2)
- non-Hodgkin's lymphoma (1)
- NUCLEOTIDES (1)
- obesity (3)
- OCCULAR (2)
- ocular hypertension (1)
- organic chemistry (12)
- osteoarthritis (2)
- PAIN (1)
- Parkinson's disease (1)
- PATENT (93)
- PATENTS (82)
- Peptide drugs (53)
- PFIZER (1)
- PHASE 1 (84)
- PHASE 3 (11)
- PHASE1 (140)
- Phase2 drugs (266)
- Phase3 drugs (301)
- plaque psoriasis (1)
- POLYMORPH (10)
- Preclinical china (14)
- Preclinical drugs (121)
- Premture ejaculation (3)
- prime designation (1)
- Priority review (88)
- PROCESS (39)
- Promising clips (9)
- Psoriasis (1)
- QbD (2)
- QIDP (23)
- radio labelled (3)
- RADIOACTIVE AGENT (3)
- RADIOLABELLED (8)
- Rare disease (3)
- RARE PEDIATRIC DISEASE REVIEW (1)
- Regenerative medicine (4)
- Regulatory (74)
- Resubmission FDA (2)
- REVIEW (10)
- rheumatoid arthritis (3)
- SCHLEROSING AGENT (2)
- Scottish Medicines Consortium (1)
- sex arousal (2)
- SFDA FAST TRACK (2)
- SINGAPORE (4)
- sNDA (12)
- sNDA JAPAN (2)
- Solid tumours (2)
- spectroscopy (16)
- SPOTLIGHT (53)
- Stem cells (3)
- SYNTHESIS (10)
- TIVE (1)
- TOXINS (1)
- Translational medicine (2)
- Transverse myletis (2)
- Tropical Disease Priority Review Voucher (1)
- UK (1)
- UNANI MEDICINE (2)
- Uncategorized (2,117)
- US HERBS (7)
- USFDA SUBMISSION (1)
- vaccine (26)
- veterinary (6)
- virus (1)
- VITAMINS (3)
- x ray contrast agent (1)
Recent Posts
- Darinaparsin June 28, 2022
- Pimitespib June 26, 2022
- VP1-001 June 20, 2022
- Vutrisiran sodium, ALN 65492, Votrisiran June 17, 2022
- DIFLUPREDNATE June 13, 2022
- COBITOLIMOD June 8, 2022
- Dr. D Srinivasa Reddy appointed Director CSIR-IICT Hyderabad India on 7th June 2022. A new assignment June 8, 2022
- ARIMOCLOMOL May 30, 2022
- IMIPRIDONE May 20, 2022
- Tirzepatide May 18, 2022
- CLOSANTEL May 12, 2022
- MONENSIN May 6, 2022
- SIBUTRAMINE April 27, 2022
- Olipudase alfa April 22, 2022
- Andexanet alfa April 20, 2022
ORGANIC SPECTROSCOPY

SUBSCRIBE

Enter your email address:
Delivered by FeedBurner
Subscribe to New Drug Approvals by EmailDR ANTHONY MELVIN CRASTO Ph.D
DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with GLENMARK LIFE SCIENCES LTD, Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 30 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, Dr T.V. Radhakrishnan and Dr B. K. Kulkarni, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 30 PLUS year tenure till date June 2021, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 9 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 90 Lakh plus views on dozen plus blogs, 233 countries, 7 continents, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 33 lakh plus views on New Drug Approvals Blog in 233 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc
Personal Links
- my sites on the net
- DR ANTHONY MELVIN CRASTO
- GOOGLE GROUP ORGANIC PROCESS DEVELOPMENT
- mixxt
- epernicus
- scipeople
- jimdo
- yolasite
- my cv
- slidestaxx
- wordpress blog
- ABOUT ME
- BRANDSITE
- SKILLPAGES
- Academia.edu
- DIIGO
- WIX
- WIX BLOG
- ISSUU
- SCRIBD
- BIZ
- GOOGLE BLOG
- APNACIRCLE
- Eurekamoments in Organic Chemistry
- Organic Chemistry by Dr Anthony
- Green Chemistry International
- Technology Transfer
- Stereochemistry
- Spectroscopy
- Polymorphism
- Reactions in Org Chem
- DR ANTHONY MELVIN CRASTO Ph.D
- Pharmaceuticals
- Medicinal chemistry
- Organic chemistry literature
- Patent related site
- Green chemistry
- Reagents
- R & D
- Molecules
- Heterocyclic chem
- Sourcing
- NEW DRUG APPROVALS
- WORLD DRUG TRACKER
- Green Chemistry International
- drug regulatory affairs international
- ORGANIC SPECTROSCOPY INTERNATIONAL
- ORGANIC SYNTHESIS INTERNATIONAL
- ALL ABOUT DRUGS
- ORGANIC CHEMISTRY INTERNATIONAL
- GOOGLE PLUS
- Drug Scaleup and Manufacturing International
- MEDICINAL CHEMISTRY INTERNATIONAL
- DRUG SYNTHESIS INTERNATIONAL
- SLIDESHARE
- DRUGS WEB
- GOOGLE SCHOLAR
- MEDCHEM-amcrasto
- ONE ORGANIC CHEMISTONE DAY
- DRUG PATENTS INTERNATIONAL
- MEDCHEM ANTHONY CRASTO
- MEDCHEM anthony crasto
- Gravatar
- ZING ME VIETNAM
- RESEARCH GATE
- AWARDS
Verified Services
Pages
- About me
- All about drugs
- Bioavailability
- CLINICAL TRIALS
- Combinatorial Chemistry in Drug Design
- DISCLAIMER
- Drug Basics
- DRUG COMPANIES
- DRUG DESIGN
- DRUG DISCOVERY
- Drug Information
- DRUG NEWS
- DRUG PORTALS
- Drug resistance
- DRUG SITES
- DRUG SYNTHESIS
- DRUGS NDA
- DRUGS, FDA2012
- FDA -US
- GMP
- HEALTH CANADA
- HELP ME/ ACCOLADES
- HSA SINGAPORE
- INDA
- KOREA DRUG APPROVAL PROCESS
- MHLW JAPAN, 厚生労働省
- NMPA CHINA
- PATENT EXPIRY DATES 1/3
- PATENT EXPIRY DATES 2/3
- PATENT EXPIRY DATES 3/3
- Patent portals
- Polymorphism
- Regulations and Guidance
- Scientificupdate (UK) on a roll
- sFDA CHINA
- SOUTH AFRICA, MCC
- SPECIAL DRUGS
- Traditional Medicine
- WHAT IS A DRUG
- World drug tracker
Archives
- June 2022 (7)
- May 2022 (5)
- April 2022 (7)
- March 2022 (7)
- February 2022 (12)
- January 2022 (15)
- December 2021 (26)
- November 2021 (17)
- October 2021 (21)
- September 2021 (21)
- August 2021 (19)
- July 2021 (13)
- June 2021 (30)
- May 2021 (7)
- April 2021 (9)
- March 2021 (25)
- February 2021 (10)
- January 2021 (17)
- December 2020 (21)
- November 2020 (5)
- October 2020 (5)
- September 2020 (12)
- August 2020 (3)
- July 2020 (5)
- June 2020 (1)
- May 2020 (1)
- April 2020 (1)
- March 2020 (19)
- February 2020 (9)
- January 2020 (12)
- December 2019 (4)
- November 2019 (4)
- October 2019 (11)
- September 2019 (8)
- August 2019 (14)
- July 2019 (23)
- June 2019 (15)
- May 2019 (16)
- April 2019 (21)
- March 2019 (14)
- February 2019 (7)
- January 2019 (17)
- December 2018 (7)
- November 2018 (14)
- October 2018 (12)
- September 2018 (18)
- August 2018 (22)
- July 2018 (15)
- June 2018 (38)
- May 2018 (14)
- April 2018 (19)
- March 2018 (25)
- February 2018 (15)
- January 2018 (17)
- December 2017 (20)
- November 2017 (15)
- October 2017 (19)
- September 2017 (8)
- August 2017 (13)
- July 2017 (11)
- June 2017 (6)
- May 2017 (10)
- April 2017 (23)
- March 2017 (18)
- February 2017 (17)
- January 2017 (15)
- December 2016 (19)
- November 2016 (31)
- October 2016 (38)
- September 2016 (33)
- August 2016 (40)
- July 2016 (53)
- June 2016 (50)
- May 2016 (50)
- April 2016 (70)
- March 2016 (45)
- February 2016 (49)
- January 2016 (42)
- December 2015 (37)
- November 2015 (37)
- October 2015 (49)
- September 2015 (35)
- August 2015 (29)
- July 2015 (25)
- June 2015 (28)
- May 2015 (21)
- April 2015 (41)
- March 2015 (51)
- February 2015 (23)
- January 2015 (33)
- December 2014 (46)
- November 2014 (31)
- October 2014 (38)
- September 2014 (74)
- August 2014 (86)
- July 2014 (101)
- June 2014 (170)
- May 2014 (98)
- April 2014 (113)
- March 2014 (80)
- February 2014 (63)
- January 2014 (70)
- December 2013 (100)
- November 2013 (91)
- October 2013 (102)
- September 2013 (104)
- August 2013 (114)
- July 2013 (129)
- June 2013 (131)
- May 2013 (155)
- April 2013 (109)
- March 2013 (105)
- February 2013 (81)
Categories
- 0rphan drug status (207)
- 2020 APPROVALS (48)
- accelerated approval (1)
- Acute Hepatic Porphyria (1)
- Acute myeloid leukaemia (1)
- African medicine (6)
- AIDS (7)
- Alzheimer's (3)
- ANAESTHETIC (1)
- anaesthetics (4)
- analgesic (2)
- ANALYTICAL (1)
- ANDA (5)
- Anthony crasto (38)
- ANTI ACNE (2)
- ANTI DIABETES (1)
- ANTI FUNGAL (6)
- ANTI INFLAMATORY (2)
- anti tubeculosis (1)
- antibacterial (9)
- Antibiotics (5)
- ANTIBODIES (54)
- ANTICONVULSANT (1)
- Antiemetic (2)
- antiglaucoma (1)
- Antihypertensives (2)
- antiinfluenza (2)
- antimalarials (12)
- Antineoplastic (6)
- antiobesity (1)
- Antispasmodic (1)
- ANTITUSSIVE (1)
- Antiulcerative (1)
- Antivirals (5)
- APPROVALS 2021 (82)
- APPROVALS 2022 (26)
- ARAB MEDICINE (5)
- Atopic dermatitis (1)
- Australia (1)
- AUSTRALIA 2021 (1)
- AWARD (11)
- AYURVEDA (78)
- Biosimilar drugs (39)
- BLA (4)
- BLOGS (26)
- Breakthrough Therapy Designation (67)
- canada (4)
- CANADA 2021 (1)
- cancer (154)
- cfda (6)
- CHINA 2011 (1)
- CHINA 2012 (1)
- CHINA 2018 (1)
- china 2019 (1)
- china pipeline (36)
- CHINESE HERBS (24)
- chronic kidney disease (1)
- CLINICAL TRIALS (10)
- COMPANIES (81)
- conference (5)
- Contrast agent (7)
- CORONAVIRUS (47)
- COVID-19 (45)
- CRL (1)
- CYSTIC FIBRIOSIS (1)
- Dengue (2)
- DIABETES (50)
- DNDi (1)
- Drug discovery (22)
- DRUG MARKETING (5)
- DRUG REVIEW (8)
- Duchenne muscular dystrophy (1)
- EMA (4)
- EU 2003 (1)
- EU 2005 (1)
- EU 2014 (5)
- EU 2015 (6)
- EU 2016 (4)
- EU 2017 (8)
- EU 2018 (5)
- EU 2020 (5)
- EU 2021 (11)
- EU 2022 (1)
- EU PIPELINE (61)
- EU SUBMISSION (32)
- EXTENDED USE (1)
- FAST TRACK FDA (74)
- FDA 15 (4)
- FDA 2010 (2)
- FDA 2011 (1)
- FDA 2012 (7)
- FDA 2013 (6)
- FDA 2014 (53)
- FDA 2015 (39)
- FDA 2016 (23)
- FDA 2017 (58)
- FDA 2018 (53)
- FDA 2019 (44)
- FDA 2020 (34)
- fda 2021 (45)
- FDA 2022 (13)
- Featured product (1)
- female sexual dysfunction (1)
- FIBROMYGALIA (1)
- flow synthesis (14)
- FORMULATION (14)
- GAIN (1)
- Gastric Proton Pump Inhibitor (1)
- Generating Antibiotic Incentives Now (1)
- GENERIC DRUG (106)
- GENERICS (22)
- glenmark (18)
- GLENMARK (16)
- GLIPTIN (1)
- GMP (10)
- gout (1)
- Greek medicine (3)
- hepatitis C viral infections (1)
- Herbals (8)
- HOMEOPATHY (3)
- HORMONE (1)
- Human medicines European Public Assessment Report EPAR (2)
- Hypertension (1)
- hypnotic (1)
- idiopathic pulmonary fibrosis (3)
- IMPLANTS (2)
- IND (1)
- IND 2017 (2)
- IND 2018 (3)
- IND 2021 (8)
- IND Filed (2)
- INDIA 2020 (5)
- INDIA 2022 (1)
- Insomnia (1)
- Investigational device exemption (IDE) approval (2)
- JAPAN 2009 (1)
- JAPAN 2013 (1)
- JAPAN 2014 (1)
- JAPAN 2015 (2)
- JAPAN 2016 (1)
- japan 2017 (6)
- JAPAN 2018 (10)
- japan 2019 (8)
- japan 2020 (10)
- JAPAN 2021 (11)
- JAPAN 2022 (10)
- Japan marketing (34)
- Japan pipeline (38)
- Korea (3)
- korea 2012 (2)
- korea 2016 (1)
- korea 2019 (1)
- Lactams (1)
- MAA (3)
- Macrolides (2)
- Malaria (17)
- MANUFACTURING (8)
- Market info (3)
- Marketing authorisation application EU (4)
- MEDICAL DEVICE (9)
- MIGRAINE (1)
- molybdenum cofactor deficiency (1)
- Monoclonal antibody (88)
- Nanotechnology (5)
- NCE (2)
- NDA (52)
- NDA JAPAN (3)
- neuropathic pain (1)
- Neutraceuticals (1)
- New Drug Application Resubmission FDA (5)
- NEW DRUGS (76)
- New drugs canada (5)
- New drugs china (6)
- New drugs EU (10)
- New drugs Japan (2)
- NEW USE DRUGS (1)
- Newzealand (2)
- NICE (2)
- non-Hodgkin's lymphoma (1)
- NUCLEOTIDES (1)
- obesity (3)
- OCCULAR (2)
- ocular hypertension (1)
- organic chemistry (12)
- osteoarthritis (2)
- PAIN (1)
- Parkinson's disease (1)
- PATENT (93)
- PATENTS (82)
- Peptide drugs (53)
- PFIZER (1)
- PHASE 1 (84)
- PHASE 3 (11)
- PHASE1 (140)
- Phase2 drugs (266)
- Phase3 drugs (301)
- plaque psoriasis (1)
- POLYMORPH (10)
- Preclinical china (14)
- Preclinical drugs (121)
- Premture ejaculation (3)
- prime designation (1)
- Priority review (88)
- PROCESS (39)
- Promising clips (9)
- Psoriasis (1)
- QbD (2)
- QIDP (23)
- radio labelled (3)
- RADIOACTIVE AGENT (3)
- RADIOLABELLED (8)
- Rare disease (3)
- RARE PEDIATRIC DISEASE REVIEW (1)
- Regenerative medicine (4)
- Regulatory (74)
- Resubmission FDA (2)
- REVIEW (10)
- rheumatoid arthritis (3)
- SCHLEROSING AGENT (2)
- Scottish Medicines Consortium (1)
- sex arousal (2)
- SFDA FAST TRACK (2)
- SINGAPORE (4)
- sNDA (12)
- sNDA JAPAN (2)
- Solid tumours (2)
- spectroscopy (16)
- SPOTLIGHT (53)
- Stem cells (3)
- SYNTHESIS (10)
- TIVE (1)
- TOXINS (1)
- Translational medicine (2)
- Transverse myletis (2)
- Tropical Disease Priority Review Voucher (1)
- UK (1)
- UNANI MEDICINE (2)
- Uncategorized (2,117)
- US HERBS (7)
- USFDA SUBMISSION (1)
- vaccine (26)
- veterinary (6)
- virus (1)
- VITAMINS (3)
- x ray contrast agent (1)
Recent Comments
DR ANTHONY MELVIN CR… on ARIMOCLOMOL | |
DR ANTHONY MELVIN CR… on LANSOPRAZOLE | |
DR ANTHONY MELVIN CR… on Molnupiravir, EIDD 2801 | |
shivkr2 on JBI-802 BY JUBILANT | |
DR ANTHONY MELVIN CR… on MAX 40279 |
SEARCH THIS BLOG
FDA approves first subcutaneous C1 Esterase Inhibitor to treat rare genetic disease
June 23, 2017 1:01 am / Leave a comment
The U.S. Food and Drug Administration today approved Haegarda, the first C1 Esterase Inhibitor (Human) for subcutaneous (under the skin) administration to prevent Hereditary Angioedema (HAE) attacks in adolescent and adult patients. The subcutaneous route of administration allows for easier at-home self-injection by the patient or caregiver, once proper training is received.
HAE, which is caused by having insufficient amounts of a plasma protein called C1-esterase inhibitor (or C1-INH), affects approximately 6,000 to 10,000 people in the U.S. People with HAE can develop rapid swelling of the hands, feet, limbs, face, intestinal tract or airway. These attacks of swelling can occur spontaneously, or can be triggered by stress, surgery or infection.
“The approval of Haegarda provides a new treatment option for adolescents and adults with Hereditary Angioedema,” said Peter Marks, M.D., Ph.D., director of FDA’s Center for Biologics Evaluation and Research. “The subcutaneous formulation allows patients to administer the product at home to help prevent attacks.”
Haegarda is a human plasma-derived, purified, pasteurized, lyophilized (freeze-dried) concentrate prepared from large pools of human plasma from U.S. donors. Haegarda is indicated for routine prophylaxis to prevent HAE attacks, but is not indicated for treatment of acute HAE attacks.
The efficacy of Haegarda was demonstrated in a multicenter controlled clinical trial. The study included 90 subjects ranging in age from 12 to 72 years old with symptomatic HAE. Subjects were randomized to receive twice per week subcutaneous doses of either 40 IU/kg or 60 IU/kg, and the treatment effect was compared to a placebo treatment period. During the 16 week treatment period, patients in both treatment groups experienced a significantly reduced number of HAE attacks compared to their placebo treatment period.
The most common side effects included injection site reactions, hypersensitivity (allergic) reactions, nasopharyngitis (swelling of the nasal passages and throat) and dizziness. Haegarda should not be used in individuals who have experienced life-threatening hypersensitivity reactions, including anaphylaxis, to a C1-INH preparation or its inactive ingredients.
Haegarda received Orphan Drug designation, which provides incentives to assist and encourage the development of drugs to treat rare diseases or conditions.
The FDA granted approval of Haegarda to CSL Behring LLC.
///////////Haegarda, C1 Esterase inhibitor, CSL Behring LLC, fda 2017, orphan drug